Molecular Neuroscience and Functional Genomics Laboratory, Department of Biotechnology, Delhi Technological University, Shahbad Daulatpur, Bawana Road, New Delhi, Delhi, 110042, India.
Mol Neurobiol. 2023 Nov;60(11):6476-6529. doi: 10.1007/s12035-023-03502-9. Epub 2023 Jul 17.
Neurodegenerative diseases (NDDs) and neuropsychiatric disorders (NPDs) are two common causes of death in elderly people, which includes progressive neuronal cell death and behavioral changes. NDDs include Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, and motor neuron disease, characterized by cognitive defects and memory impairment, whereas NPDs include depression, seizures, migraine headaches, eating disorders, addictions, palsies, major depressive disorders, anxiety, and schizophrenia, characterized by behavioral changes. Mounting evidence demonstrated that NDDs and NPDs share an overlapping mechanism, which includes post-translational modifications, the microbiota-gut-brain axis, and signaling events. Mounting evidence demonstrated that various drug molecules, namely, natural compounds, repurposed drugs, multitarget directed ligands, and RNAs, have been potentially implemented as therapeutic agents against NDDs and NPDs. Herein, we highlighted the overlapping mechanism, the role of anxiety/stress-releasing factors, cytosol-to-nucleus signaling, and the microbiota-gut-brain axis in the pathophysiology of NDDs and NPDs. We summarize the therapeutic application of natural compounds, repurposed drugs, and multitarget-directed ligands as therapeutic agents. Lastly, we briefly described the application of RNA interferences as therapeutic agents in the pathogenesis of NDDs and NPDs. Neurodegenerative diseases and neuropsychiatric diseases both share a common signaling molecule and molecular phenomenon, namely, pro-inflammatory cytokines, γCaMKII and MAPK/ERK, chemokine receptors, BBB permeability, and the gut-microbiota-brain axis. Studies have demonstrated that any alterations in the signaling mentioned above molecules and molecular phenomena lead to the pathophysiology of neurodegenerative diseases, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and neuropsychiatric disorders, such as bipolar disorder, schizophrenia, depression, anxiety, autism spectrum disorder, and post-traumatic stress disorder.
神经退行性疾病(NDDs)和神经精神疾病(NPDs)是老年人常见的两种死亡原因,包括进行性神经元细胞死亡和行为改变。NDDs 包括阿尔茨海默病、帕金森病、亨廷顿病、肌萎缩侧索硬化症、多发性硬化症和运动神经元病,其特征是认知缺陷和记忆障碍,而 NPDs 包括抑郁症、癫痫发作、偏头痛、饮食障碍、成瘾、瘫痪、重度抑郁症、焦虑症和精神分裂症,其特征是行为改变。越来越多的证据表明,NDDs 和 NPDs 具有重叠的机制,包括翻译后修饰、微生物群-肠道-大脑轴和信号事件。越来越多的证据表明,各种药物分子,即天然化合物、再利用药物、多靶点定向配体和 RNA,已被潜在地用作治疗 NDDs 和 NPDs 的治疗剂。在此,我们强调了重叠的机制、焦虑/应激释放因子的作用、细胞质到核的信号转导以及微生物群-肠道-大脑轴在 NDDs 和 NPDs 发病机制中的作用。我们总结了天然化合物、再利用药物和多靶点定向配体作为治疗剂的治疗应用。最后,我们简要描述了 RNA 干扰作为治疗剂在 NDDs 和 NPDs 发病机制中的应用。神经退行性疾病和神经精神疾病都有一个共同的信号分子和分子现象,即促炎细胞因子、γCaMKII 和 MAPK/ERK、趋化因子受体、血脑屏障通透性和肠道-微生物群-大脑轴。研究表明,上述分子和分子现象的任何改变都会导致神经退行性疾病的发病机制,如阿尔茨海默病、帕金森病、亨廷顿病和肌萎缩侧索硬化症,以及神经精神疾病,如双相情感障碍、精神分裂症、抑郁症、焦虑症、自闭症谱系障碍和创伤后应激障碍。